To launch National Addictions Awareness Week, Canada’s Federal Minister of Health Leona Aglukkaq, and Shelly Glover, Parliamentary Secretary to the Minister of Finance, announced tough new licensing rules that aim to clamp down on the diversion of controlled release formulations of oxycodone products - prescription drugs that are at a high risk of abuse.
In a letter to her provincial and territorial counterparts, Ms Aglukkaq called on provincial and territorial governments, as well as medical professionals, to look at what they can do within their areas of jurisdiction to tackle the serious problem of prescription drug abuse.
"Our government is taking action to tackle prescription drug abuse," said Ms Aglukkaq, adding: "This is a serious issue that destroys the lives of individuals and families, and I believe we have the responsibility to work with the provinces and territories to address it head-on."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze